Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.51 |
| ▸ | RORC | P51449 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3365854 | 0.87 | KEAP1 (0.73) | KEAP1NFE2L2HCRTR2PTGER1PPARG | |
| SCHEMBL3365552 | 0.78 | MAPT (0.62) | KEAP1NFE2L2ALDH1A1TSHRLMNA | |
| SCHEMBL3369314 | 0.77 | ALDH1A1 (0.46) | KEAP1NFE2L2ALDH1A1HCRTR2PTGER1 | |
| SCHEMBL3369317 | 0.77 | ALDH1A1 (0.46) | KEAP1NFE2L2ALDH1A1HCRTR2PTGER1 | |
| SCHEMBL3368625 | 0.76 | TSHR (0.58) | KEAP1NFE2L2ALDH1A1TSHRRORC | |
| SCHEMBL3366973 | 0.74 | OXTR (0.61) | ALDH1A1TSHRPTGER1SMN1; SMN2MEN1 | |
| SCHEMBL24279587 | 0.73 | KEAP1 (0.65) | KEAP1NFE2L2ALDH1A1TSHRHCRTR2 | |
| SCHEMBL364573 | 0.72 | FFAR1 (0.55) | ALDH1A1LMNAKDM4E | |
| SCHEMBL24279547 | 0.70 | RORC (0.61) | KEAP1NFE2L2ALDH1A1TSHRHCRTR2 | |
| SCHEMBL16557464 | 0.69 | SMN1; SMN2 (0.71) | KEAP1NFE2L2ALDH1A1RORCSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335901-B1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | MERCK SERONO SA (CH) | 2010-04-14 | — | — | EP | disclosed |
| US-7312358-B2 | Pharmaceutically active sulfanilide derivatives | LABORATOIRES SERONO SA (CH) | 2007-12-25 | — | — | US | disclosed |
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | MERCK SERONO SA (CH) | 2004-04-15 | — | — | US | disclosed |
| EP-1335901-A1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002032864-A1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | OXTR, AVPR2, OPRL1 | KEAP1 2923/4885NFE2L2 1276/4885ALDH1A1 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.